Overview
Advertisement BMC Medicine volume 20, Article number: 37 (202) Cite this article 471 Aceses1 AltmetricMetrics detailsDiabetic kidney disease (DKD), the most comon cause of kidney failure and end-stage kidney disease worldwide, wil develop in almost half of al people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance.This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities.
Key Information
The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blod presure management, have only modest efects on minimizing glomerular filtration rate decline or progresion to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive efect of SGLT-2i on several kidney disease-related endpoints, the efect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established.
Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective efects.With these new agents and the promise of aditional agents under clinical development, clinicians wil be more able to personalize treatment of DKD in patients with type 2 diabetes. Per Review reports Acording to the International Diabetes Federation, 537 milion adults (20–79 years of age) were living with diabetes melitus worldwide in 2021, and this number is expected to increase to more than 780 milion by the year 2045 [1].
Of these, an estimated 90–95% have type 2 diabetes (T2D) [2, 3]. Among people with T2D, nearly half wil develop diabetic kidney disease (DKD), previously termed “diabetic nephropathy” [4, 5]. DKD is the most comon cause of kidney failure and end-stage kidney disease (ESKD) leading to the ned for kidney replacement therapy (dialysis or transplant) in the world [6, 7].
Summary
Moreover, DKD is a leading cause of cardio